PamGene

PamGene is a biotechnology firm specializing in multiplex kinase activity profiling technology, providing innovative solutions to enhance patient treatment and disease understanding. PamGene operates in the biotechnology sector, focusing on multiplex kinase activity profiling. The company is headquartered in 's-Hertogenbosch, Netherlands. PamGene has received a total funding of EUR 10.

000 mn, with its latest funding round being a Grant amounting to EUR 2. 000 mn from SenterNovem. The company has completed 7 deals to date. PamGene specializes in advanced biotechnology solutions that focus on multiplex kinase activity profiling technology.

Their core offerings support physicians and scientists in optimizing patient treatment and understanding diseases. The flagship product measures cellular kinome activity in real time, aiding biomarker discovery, patient stratification, and therapy selection, especially for cancer applications. PamGene's technology is utilized across clinical, translational, and pre-clinical settings to analyze drug responses and optimize kinase inhibitors. Their services are offered to pharmaceutical and biotech companies, research institutions, and healthcare providers in Europe, North America, and Asia.

PamGene generates revenue through its Contract Research Services and Diagnostic Assay Services (DAS), which are designed for partnerships with pharmaceutical and biotechnology firms. Clients engage PamGene for expertise in kinase profiling and biomarker discovery, utilizing the company’s advanced infrastructure and skilled personnel. The transaction model operates on a B2B basis, with clients commissioning specific assays or services tailored to their research. Revenue includes agreements for one-off projects and ongoing collaborations requiring repeated services over time.

PamGene’s DAS facility is ISO13485 compliant, emphasizing quality in delivering in-vitro diagnostic assays. PamGene plans to expand its product offerings and enhance its market presence. Recent funding will support the development of new products and services aimed at improving patient outcomes in oncology. The company is also focusing on market expansion in Europe, North America, and Asia, leveraging its existing partnerships and technological advancements.

This strategic growth is supported by the recent Grant funding received, which will facilitate new product designs and potential market entry initiatives.